NYSE:ZBH - Zimmer Biomet Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$111.08 -0.66 (-0.59 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$111.08
Today's Range$110.87 - $112.98
52-Week Range$104.28 - $133.49
Volume786,937 shs
Average Volume1.35 million shs
Market Capitalization$22.71 billion
P/E Ratio13.83
Dividend Yield0.86%
Beta1.16

About Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet logoZimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSE:ZBH
CUSIPN/A
Phone574-267-6131

Debt

Debt-to-Equity Ratio0.79
Current Ratio1.69
Quick Ratio1.07

Price-To-Earnings

Trailing P/E Ratio13.83
Forward P/E Ratio14.48
P/E Growth2.18

Sales & Book Value

Annual Sales$7.82 billion
Price / Sales2.89
Cash Flow$14.8701 per share
Price / Cash7.47
Book Value$59.03 per share
Price / Book1.88

Profitability

EPS (Most Recent Fiscal Year)$8.03
Net Income$1.81 billion
Net Margins21.81%
Return on Equity14.36%
Return on Assets6.02%

Miscellaneous

Employees18,200
Outstanding Shares203,270,000

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet announced a quarterly dividend on Monday, March 12th. Shareholders of record on Thursday, March 29th will be paid a dividend of $0.24 per share on Monday, April 30th. This represents a $0.96 annualized dividend and a yield of 0.86%. The ex-dividend date is Wednesday, March 28th. View Zimmer Biomet's Dividend History.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet (NYSE:ZBH) posted its quarterly earnings data on Thursday, April, 26th. The medical equipment provider reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.89 by $0.02. The medical equipment provider had revenue of $2.02 billion for the quarter, compared to analysts' expectations of $1.98 billion. Zimmer Biomet had a net margin of 21.81% and a return on equity of 14.36%. Zimmer Biomet's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.13 earnings per share. View Zimmer Biomet's Earnings History.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Zimmer Biomet.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share guidance of $7.60-$7.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.80. The company issued revenue guidance of $7.94-$8.09 billion, compared to the consensus revenue estimate of $7.96 billion.

What price target have analysts set for ZBH?

24 brokers have issued twelve-month price objectives for Zimmer Biomet's shares. Their forecasts range from $115.00 to $168.00. On average, they anticipate Zimmer Biomet's share price to reach $137.7143 in the next year. View Analyst Ratings for Zimmer Biomet.

What are Wall Street analysts saying about Zimmer Biomet stock?

Here are some recent quotes from research analysts about Zimmer Biomet stock:
  • 1. According to Zacks Investment Research, "Zimmer Biomet posted better-than-expected performance in first-quarter 2018. However, the year-over-year decline in earnings and revenues made investors jittery.  Declining sales at Knees, Hips and other segments at CER were a major disappointment. According to the company, slower pace of supply recovery and sales recapture related to major brands within the company’s Knee, Hip and S.E.T. segments marred the quarterly performance. Also, escalating costs and expenses impacted margins. In the past three months, Zimmer Biomet has been observed to underperform its industry. On the bright side, the company’s consistent efforts in product and renovation through research and development raise hopes. We are optimistic about synergies from the LDR buyout as well. We are also impressed by the strategic and financial goals which the combined entity expects to reach." (4/27/2018)
  • 2. Canaccord Genuity analysts commented, "We are updating our model to reflect Zimmer’s adoption of several previously disclosed new accounting standards (revenue recognition for customer contracts, reporting of pension costs, and hedging activities). The company adopted the changes effective January 1, 2018, and recently provided updated historical financials (for 2016 and 2017) to reflect a retrospective adoption of the new standards. While the new accounting policies have not resulted in any material changes to 2016 and 2017 historical results, we have nonetheless updated our model to reflect how the company will report moving forward. Additionally, we have also tweaked our forward estimates to incorporate a slightly more conservative revenue ramp in 2018/2019 and higher COGS and operating spend related to the quality/manufacturing remediation and sales channel incentives/ investments. Thus we maintain our HOLD rating and lower our price target to $121." (4/12/2018)
  • 3. Cantor Fitzgerald analysts commented, "ZBH received FDA clearance for its Persona cementless knee, earlier than we expected." (2/5/2018)

Who are some of Zimmer Biomet's key competitors?

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the folowing people:
  • Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 54)
  • Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 46)
  • Dr. Katarzyna Mazur-Hofsaess, Pres of Europe, Middle East & Africa (Age 54)
  • Mr. Sang Yi, Pres of Asia Pacific (Age 56)
  • Mr. Bryan C. Hanson, Pres, CEO & Director (Age 51)

Has Zimmer Biomet been receiving favorable news coverage?

News headlines about ZBH stock have trended positive this week, Accern reports. The research group rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zimmer Biomet earned a news sentiment score of 0.30 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 44.00 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.55%), Massachusetts Financial Services Co. MA (7.41%), JPMorgan Chase & Co. (4.84%), American Century Companies Inc. (2.48%), Northern Trust Corp (1.77%) and Wells Fargo & Company MN (1.14%). Company insiders that own Zimmer Biomet stock include Bryan C Hanson, Chad F Phipps, Daniel E Williamson, Daniel P Florin, David A Jr Nolan, David C Dvorak, Katarzyna Mazur-Hofsaess, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.

Which major investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, OppenheimerFunds Inc., Northern Trust Corp, BlackRock Inc., Franklin Resources Inc., Swiss National Bank, Stifel Financial Corp and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, Katarzyna Mazur-Hofsaess, Sang Yi and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet.

Which major investors are buying Zimmer Biomet stock?

ZBH stock was purchased by a variety of institutional investors in the last quarter, including Ceredex Value Advisors LLC, PointState Capital LP, JPMorgan Chase & Co., Wells Fargo & Company MN, American Century Companies Inc., Darrell & King LLC, Thompson Siegel & Walmsley LLC and Stevens Capital Management LP. View Insider Buying and Selling for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $111.08.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $22.71 billion and generates $7.82 billion in revenue each year. The medical equipment provider earns $1.81 billion in net income (profit) each year or $8.03 on an earnings per share basis. Zimmer Biomet employs 18,200 workers across the globe.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]


MarketBeat Community Rating for Zimmer Biomet (ZBH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  599 (Vote Outperform)
Underperform Votes:  470 (Vote Underperform)
Total Votes:  1,069
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Zimmer Biomet (NYSE:ZBH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
24 Wall Street analysts have issued ratings and price targets for Zimmer Biomet in the last 12 months. Their average twelve-month price target is $137.7143, suggesting that the stock has a possible upside of 23.98%. The high price target for ZBH is $168.00 and the low price target for ZBH is $115.00. There are currently 6 hold ratings, 17 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.792.782.862.61
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
17 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
16 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
16 Buy Rating(s)
1 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $137.7143$138.80$141.6667$133.7143
Price Target Upside: 23.98% upside30.43% upside11.39% upside20.40% upside

Zimmer Biomet (NYSE:ZBH) Consensus Price Target History

Price Target History for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE:ZBH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/27/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$148.00 ➝ $140.00LowView Rating Details
4/27/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Market Outperform$145.00 ➝ $133.00LowView Rating Details
4/27/2018Needham & Company LLCLower Price TargetStrong-Buy ➝ Strong-Buy$155.00 ➝ $146.00MediumView Rating Details
4/12/2018Canaccord GenuityReiterated RatingHold$121.00LowView Rating Details
4/2/2018Evercore ISIInitiated CoverageIn-Line$115.00LowView Rating Details
3/23/2018Robert W. BairdDowngradeOutperform ➝ NeutralHighView Rating Details
3/15/2018OppenheimerInitiated CoverageOutperform$135.00LowView Rating Details
3/15/2018Raymond JamesInitiated CoverageOutperform$135.00LowView Rating Details
2/27/2018CitigroupLower Price TargetNeutral ➝ Neutral$132.00 ➝ $121.00LowView Rating Details
2/5/2018Cantor FitzgeraldReiterated RatingBuy$140.00HighView Rating Details
1/31/2018Leerink SwannBoost Price TargetOutperform ➝ Outperform$142.00 ➝ $146.00LowView Rating Details
1/31/2018Stifel NicolausUpgradeHold ➝ Buy$120.00 ➝ $168.00LowView Rating Details
1/30/2018BMO Capital MarketsReiterated RatingBuy$144.00LowView Rating Details
1/29/2018SunTrust BanksBoost Price TargetBuy$142.00MediumView Rating Details
12/19/2017Goldman Sachs GroupUpgradeSell ➝ Neutral$125.00LowView Rating Details
12/19/2017Wells Fargo & CoUpgradeMarket Perform ➝ OutperformLowView Rating Details
11/14/2017Deutsche BankUpgradeHold ➝ Buy$128.00N/AView Rating Details
11/9/2017Edward JonesUpgradeHold ➝ BuyN/AView Rating Details
11/7/2017Royal Bank of CanadaLower Price TargetOutperform$125.00N/AView Rating Details
11/3/2017Jefferies GroupReiterated RatingBuy$136.00N/AView Rating Details
11/2/2017Piper Jaffray CompaniesDowngradeOverweight ➝ NeutralN/AView Rating Details
8/24/2017GabelliInitiated CoverageBuy$142.00LowView Rating Details
7/14/2017Bank of AmericaReiterated RatingBuy ➝ Buy$158.00MediumView Rating Details
7/12/2017GuggenheimUpgradeNeutral ➝ Buy$157.00MediumView Rating Details
1/5/2017JPMorgan Chase & Co.Set Price TargetBuy$134.00N/AView Rating Details
12/21/2016UBSDowngradeNeutral ➝ Sell$113.00 ➝ $100.00N/AView Rating Details
11/8/2016Northcoast ResearchDowngradeBuy ➝ NeutralN/AView Rating Details
9/22/2016ArgusReiterated RatingBuy$140.00N/AView Rating Details
8/23/2016BarclaysBoost Price TargetOverweight$140.00 ➝ $145.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Zimmer Biomet (NYSE:ZBH) Earnings History and Estimates Chart

Earnings by Quarter for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE:ZBH) Earnings Estimates

2018 EPS Consensus Estimate: $7.70
2019 EPS Consensus Estimate: $8.01
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20186$1.85$1.98$1.89
Q2 20187$1.85$1.97$1.90
Q3 20187$1.70$1.78$1.75
Q4 20187$2.09$2.23$2.15
Q1 20194$1.95$2.03$1.99
Q2 20194$1.96$2.01$1.99
Q3 20194$1.78$1.86$1.82
Q4 20194$2.12$2.27$2.21

Zimmer Biomet (NYSE ZBH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018$1.90N/AView Earnings Details
4/26/2018Q1 2018$1.89$1.91$1.9805 billion$2.0180 billionViewN/AView Earnings Details
1/30/2018Q4 2017$2.0980$2.10$2.0286 billion$2.0743 billionViewListenView Earnings Details
11/1/2017Q3 2017$1.74$1.72$1.8291 billion$1.8180 billionViewN/AView Earnings Details
7/27/2017Q2 2017$2.10$2.08$1.9541 billion$1.9544 billionViewN/AView Earnings Details
4/27/2017Q1 2017$2.1110$2.13$1.9607 billion$1.9773 billionViewN/AView Earnings Details
1/31/2017Q416$2.11$2.14$1.98 billion$2.01 billionViewListenView Earnings Details
10/31/2016Q316$1.79$1.79$950.20 million$1.83 billionViewListenView Earnings Details
7/28/2016Q216$1.97$2.02$1.90 billion$1.93 billionViewListenView Earnings Details
4/28/2016Q116$1.93$2.00$1.88 billion$1.90 billionViewListenView Earnings Details
1/28/2016Q415$2.04$2.09$1.96 billion$1.98 billionViewListenView Earnings Details
10/29/2015Q315$1.56$1.64$1.76 billion$1.76 billionViewListenView Earnings Details
7/30/2015Q2 2015$1.56$1.59$1.1429 billion$1.1676 billionViewN/AView Earnings Details
4/30/2015Q115$1.54$1.58$1.15 billion$1.13 billionViewN/AView Earnings Details
1/29/2015Q414$1.71$0.91$1.25 billion$1.22 billionViewN/AView Earnings Details
10/23/2014Q314$1.00$0.96$1.10 billion$1.11 billionViewListenView Earnings Details
7/24/2014Q214$1.49$1.49$1.21 billion$1.18 billionViewN/AView Earnings Details
4/24/2014Q114$1.47$1.50$1.18 billion$1.16 billionViewListenView Earnings Details
1/31/2014Q114$1.62$1.36$1.22 billion$1.24 billionViewN/AView Earnings Details
10/24/2013Q313$1.24$1.25$1.06 billion$1.07 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.43$1.15 billion$1.17 billionViewN/AView Earnings Details
4/25/2013Q1 2013$1.40$1.41$1.14 billion$1.14 billionViewN/AView Earnings Details
1/31/2013Q4 2012$1.49$1.51$1.17 billion$1.18 billionViewN/AView Earnings Details
10/25/2012$1.13$1.15ViewN/AView Earnings Details
7/26/2012$1.32$1.34ViewN/AView Earnings Details
4/26/2012$1.30$1.30ViewN/AView Earnings Details
1/26/2012$1.34$1.36ViewN/AView Earnings Details
10/27/2011$1.03$1.04ViewN/AView Earnings Details
7/27/2011$1.19$1.21ViewN/AView Earnings Details
4/28/2011$1.12$1.19ViewN/AView Earnings Details
1/27/2011$1.19$1.21ViewN/AView Earnings Details
10/28/2010Q3 2010$0.95$0.96ViewN/AView Earnings Details
7/22/2010Q2 2010$1.05$1.09ViewN/AView Earnings Details
4/22/2010Q1 2010$1.01$1.02ViewN/AView Earnings Details
1/28/2010Q4 2009$1.08$1.12ViewN/AView Earnings Details
10/22/2009Q3 2009$0.85$0.88ViewN/AView Earnings Details
7/23/2009Q2 2009$0.96$1.01ViewN/AView Earnings Details
4/23/2009Q1 2009$0.94$0.95ViewN/AView Earnings Details
1/29/2009Q4 2008$1.00$1.00ViewN/AView Earnings Details
10/23/2008Q3 2008$0.89$0.97ViewN/AView Earnings Details
7/22/2008Q2 2008$1.03$1.03ViewN/AView Earnings Details
4/24/2008Q1 2008$1.04$1.04ViewN/AView Earnings Details
1/29/2008Q4 2007$1.04$1.18ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Zimmer Biomet (NYSE:ZBH) Dividend Information

Zimmer Biomet pays an annual dividend of $0.96 per share, with a dividend yield of 0.86%. ZBH's most recent quarterly dividend payment was Monday, April 30. Zimmer Biomet pays out 11.96% of its earnings out as a dividend.
Most Recent Dividend:4/30/2018
Annual Dividend:$0.96
Dividend Yield:0.86%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio(s):11.96% (Trailing 12 Months of Earnings)
12.52% (Based on This Year's Estimates)
11.97% (Based on Next Year's Estimates)
6.46% (Based on Cash Flow)
Track Record:2 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE:ZBH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/12/2018quarterly$0.240.88%3/28/20183/29/20184/30/2018
12/18/2017quarterly$0.240.79%12/28/201712/29/20171/29/2018
8/7/2017quarterly$0.240.83%9/21/20179/22/201710/27/2017
5/30/2017quarterly$0.240.81%6/21/20176/23/20177/28/2017
3/1/2017quarterly$0.240.81%3/29/20173/31/20174/28/2017
12/19/2016quarterly$0.240.94%12/28/201612/30/20161/27/2017
8/23/2016quarterly$0.240.74%9/21/20169/23/201610/28/2016
5/23/2016quarterly$0.246/22/20166/24/20167/29/2016
2/24/2016quarterly$0.240.99%3/29/20163/31/20164/29/2016
12/14/2015quarterly$0.220.87%12/29/201512/31/20151/29/2016
8/24/2015quarterly$0.220.9%9/28/20159/30/201510/30/2015
5/5/2015quarterly$0.220.8%5/13/20155/15/20157/14/2015
2/24/2015quarterly$0.220.73%3/4/20153/6/20154/24/2015
12/15/2014quarterly$0.220.81%12/24/201412/29/20141/30/2015
8/26/2014quarterly$0.220.87%9/24/20149/26/201410/31/2014
5/23/2014quarterly$0.220.86%6/25/20146/27/20147/25/2014
3/5/2014quarterly$0.220.9%3/26/20143/28/20144/25/2014
12/16/2013quarterly$0.200.88%12/24/201312/27/20131/31/2014
9/9/2013quarterly$0.200.99%9/25/20139/27/201310/25/2013
6/14/2013quarterly$0.201.03%6/26/20136/28/20137/26/2013
3/8/2013quarterly$0.201.06%3/26/20133/29/20134/26/2013
12/14/2012quarterly$0.181.06%12/24/201212/27/20121/25/2013
(Data available from 1/1/2013 forward)

Insider Trades

Zimmer Biomet (NYSE ZBH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.71%
Institutional Ownership Percentage: 87.42%
Insider Trading History for Zimmer Biomet (NYSE:ZBH)
Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE ZBH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/22/2018Katarzyna Mazur-HofsaessInsiderSell8,765$113.61$995,791.6525,447View SEC Filing  
4/30/2018Tony W CollinsVPSell1,330$116.73$155,250.90View SEC Filing  
2/20/2018Bryan C HansonInsiderBuy25,077$119.68$3,001,215.36View SEC Filing  
2/12/2018Chad F. PhippsVPSell20,826$115.95$2,414,774.70View SEC Filing  
7/31/2017Tony W. CollinsVPSell16,986$121.74$2,067,875.64View SEC Filing  
6/12/2017Sang YiInsiderSell17,731$124.56$2,208,573.36View SEC Filing  
5/5/2017Chad F. PhippsVPSell6,200$116.76$723,912.00View SEC Filing  
4/27/2017David C DvorakInsiderSell87,331$116.47$10,171,441.57381,886View SEC Filing  
3/20/2017David C DvorakInsiderSell1,040$121.63$126,495.20294,077View SEC Filing  
12/2/2016David A. Jr. NolanInsiderSell5,050$101.11$510,605.50View SEC Filing  
9/8/2016Daniel E WilliamsonInsiderSell2,716$129.96$352,971.362,000View SEC Filing  
8/23/2016Stuart G KleopferInsiderSell3,397$129.71$440,624.873,000View SEC Filing  
8/12/2016Tony W. CollinsVPSell1,287$129.16$166,228.92View SEC Filing  
8/9/2016Stuart G KleopferInsiderSell533$132.71$70,734.436,397View SEC Filing  
8/1/2016David A. Jr. NolanInsiderSell25,255$130.77$3,302,596.35View SEC Filing  
7/11/2016Daniel P FlorinCFOSell15,000$124.98$1,874,700.0016,983View SEC Filing  
6/14/2016Tony W CollinsCAOSell3,611$116.43$420,428.733,245View SEC Filing  
6/9/2016Stuart G KleopferInsiderSell11,000$119.45$1,313,950.007,609View SEC Filing  
4/14/2016Daniel P FlorinCFOSell10,000$114.98$1,149,800.0028,415View SEC Filing  
4/12/2016Daniel P FlorinCFOSell12,000$110.00$1,320,000.0038,415View SEC Filing  
3/21/2016David C DvorakCEOSell1,540$104.16$160,406.40277,416View SEC Filing  
2/10/2016Blackstone Capital Partners VMajor ShareholderSell7,351,708$95.91$705,102,314.28View SEC Filing  
1/8/2016David C. DvorakCEOSell44,661$102.46$4,575,966.06244,502View SEC Filing  
12/2/2015David A. Jr. NolaninsiderSell3,435$102.62$352,499.7012,139View SEC Filing  
6/30/2015Adam Rudolph JohnsonInsiderSell30,600$110.34$3,376,404.00View SEC Filing  
6/29/2015Daniel E WilliamsonInsiderSell16,000$110.98$1,775,680.00View SEC Filing  
6/29/2015Daniel P FlorinCFOSell5,000$107.00$535,000.00View SEC Filing  
3/17/2015David C DvorakCEOSell1,300$115.55$150,215.00View SEC Filing  
12/5/2014David C DvorakCEOSell48,703$115.00$5,600,845.00View SEC Filing  
11/28/2014Chad F PhippsVPSell5,000$112.00$560,000.00View SEC Filing  
11/3/2014Katarzyna Mazur-HofsaessInsiderSell28,253$110.01$3,108,112.53View SEC Filing  
9/9/2014Stephen Hong Liang OoiInsiderSell40,768$102.78$4,190,135.04View SEC Filing  
8/26/2014James T CrinesCFOSell40,768$101.00$4,117,568.00View SEC Filing  
1/8/2014Jeffery MccaulleyInsiderSell21,286$96.00$2,043,456.005,211View SEC Filing  
1/7/2014Chad PhippsVPSell7,000$95.00$665,000.0017,240View SEC Filing  
12/20/2013Jeffery MccaulleyInsiderSell21,286$93.00$1,979,598.005,211View SEC Filing  
12/3/2013Jeffery MccaulleyInsiderSell2,713$90.12$244,495.565,211View SEC Filing  
11/15/2013Derek DavisCAOSell3,500$90.20$315,700.002,791View SEC Filing  
11/14/2013Chad PhippsVPSell7,800$90.00$702,000.0017,240View SEC Filing  
11/14/2013David DvorakCEOSell64,763$90.00$5,828,670.00172,746View SEC Filing  
11/14/2013Jeffery MccaulleyInsiderSell21,285$90.00$1,915,650.007,924View SEC Filing  
9/13/2013Katarzyna Mazur-HofsaessInsiderSell4,890$81.38$397,948.201,643View SEC Filing  
8/1/2013James T CrinesCFOSell46,200$84.56$3,906,672.00View SEC Filing  
8/1/2013Stephen Hong Liang OoiInsiderSell38,500$84.27$3,244,395.00View SEC Filing  
7/29/2013Derek M DavisCAOSell3,725$83.78$312,080.50View SEC Filing  
7/29/2013Jeffery A MccaulleyInsiderSell112,255$83.40$9,362,067.00View SEC Filing  
7/19/2013Chad F PhippsVPSell6,000$83.00$498,000.00View SEC Filing  
5/8/2013Chad F PhippsVPSell5,000$77.26$386,300.00View SEC Filing  
4/30/2013James T CrinesCFOSell25,000$76.08$1,902,000.00View SEC Filing  
4/30/2013Jeffery A MccaulleyInsiderSell10,000$76.08$760,800.00View SEC Filing  
2/4/2013Derek M DavisCAOSell21,864$72.53$1,585,795.92View SEC Filing  
2/4/2013Jeffery A MccaulleyInsiderSell12,000$73.60$883,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Zimmer Biomet (NYSE ZBH) News Headlines

Source:
DateHeadline
FDA clears Zimmer Biomets 3D-printed lumbar cagesFDA clears Zimmer Biomet's 3D-printed lumbar cages
seekingalpha.com - May 24 at 8:40 AM
Zimmer Biomet (ZBH) Insider Sells $995,791.65 in StockZimmer Biomet (ZBH) Insider Sells $995,791.65 in Stock
www.americanbankingnews.com - May 23 at 7:16 PM
BRIEF-Zimmer Biomet Holdings Announces 510(K) Clearance For Zyston Strut Open Titanium Interbody Spacer SystemBRIEF-Zimmer Biomet Holdings Announces 510(K) Clearance For Zyston Strut Open Titanium Interbody Spacer System
www.reuters.com - May 23 at 5:15 PM
Zimmer Biomet New System Gets FDA Nod, to Boost Spine WingZimmer Biomet New System Gets FDA Nod, to Boost Spine Wing
www.zacks.com - May 23 at 8:36 AM
Zimmer Biomet Announces 510(k) Clearance for Zyston® Strut Open Titanium Interbody Spacer SystemZimmer Biomet Announces 510(k) Clearance for Zyston® Strut Open Titanium Interbody Spacer System
finance.yahoo.com - May 23 at 8:36 AM
Generac, Maximus, Norbord, Boeing and Zimmer Biomet as Zacks Bull and Bear of the DayGenerac, Maximus, Norbord, Boeing and Zimmer Biomet as Zacks Bull and Bear of the Day
finance.yahoo.com - May 23 at 8:36 AM
3 Stocks Back In Play After U.S.-China Trade War Stalls3 Stocks Back In Play After U.S.-China Trade War Stalls
finance.yahoo.com - May 22 at 4:54 PM
Head to Head Comparison: Rewalk Robotics (RWLK) versus Zimmer Biomet (ZBH)Head to Head Comparison: Rewalk Robotics (RWLK) versus Zimmer Biomet (ZBH)
www.americanbankingnews.com - May 21 at 9:18 PM
Zimmer Biomet Announces Call for Applications for the 2018 Connected Health Innovation AwardZimmer Biomet Announces Call for Applications for the 2018 Connected Health Innovation Award
finance.yahoo.com - May 21 at 8:37 AM
Head-To-Head Survey: Zimmer Biomet (ZBH) & William Demant (WILYY)Head-To-Head Survey: Zimmer Biomet (ZBH) & William Demant (WILYY)
www.americanbankingnews.com - May 20 at 5:18 PM
Financial Contrast: Zimmer Biomet (ZBH) vs. Align Technology (ALGN)Financial Contrast: Zimmer Biomet (ZBH) vs. Align Technology (ALGN)
www.americanbankingnews.com - May 16 at 11:14 PM
$2.00 Billion in Sales Expected for Zimmer Biomet (ZBH) This Quarter$2.00 Billion in Sales Expected for Zimmer Biomet (ZBH) This Quarter
www.americanbankingnews.com - May 16 at 4:04 AM
$1.88 Earnings Per Share Expected for Zimmer Biomet (ZBH) This Quarter$1.88 Earnings Per Share Expected for Zimmer Biomet (ZBH) This Quarter
www.americanbankingnews.com - May 14 at 5:19 AM
Zimmer Biomet (ZBH) vs. RTI Surgical (RTIX) Head-To-Head SurveyZimmer Biomet (ZBH) vs. RTI Surgical (RTIX) Head-To-Head Survey
www.americanbankingnews.com - May 10 at 9:23 PM
Recent Analysis Shows Amkor Technology, Nielsen Holdings Plc, Dean Foods, Citizens Financial Group, The Bank of New York Mellon, and Zimmer Biomet Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows Amkor Technology, Nielsen Holdings Plc, Dean Foods, Citizens Financial Group, The Bank of New York Mellon, and Zimmer Biomet Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - May 10 at 8:51 AM
Zimmer Biomet (ZBH) Given Consensus Rating of "Buy" by BrokeragesZimmer Biomet (ZBH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 10 at 5:36 AM
Reviewing Zimmer Biomet (ZBH) & Invacare (IVC)Reviewing Zimmer Biomet (ZBH) & Invacare (IVC)
www.americanbankingnews.com - May 8 at 9:26 PM
Zimmer Biomet Holdings to Present at the Bank of America Merrill Lynch 2018 Health Care ConferenceZimmer Biomet Holdings to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 7 at 5:17 PM
Zimmer Biomet Holdings to Present at Deutsche Bank 43rd Annual Health Care ...Zimmer Biomet Holdings to Present at Deutsche Bank 43rd Annual Health Care ...
www.prnewswire.com - May 4 at 8:40 AM
Zimmer Biomet Holdings to Present at Deutsche Bank 43rd Annual Health Care ConferenceZimmer Biomet Holdings to Present at Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 3 at 5:04 PM
Zimmer Biomet to Post FY2018 Earnings of $7.70 Per Share, Cantor Fitzgerald Forecasts (ZBH)Zimmer Biomet to Post FY2018 Earnings of $7.70 Per Share, Cantor Fitzgerald Forecasts (ZBH)
www.americanbankingnews.com - May 2 at 9:26 AM
Q3 2018 EPS Estimates for Zimmer Biomet Reduced by SunTrust Banks (ZBH)Q3 2018 EPS Estimates for Zimmer Biomet Reduced by SunTrust Banks (ZBH)
www.americanbankingnews.com - May 2 at 9:10 AM
Tony W. Collins Sells 1,330 Shares of Zimmer Biomet (ZBH) StockTony W. Collins Sells 1,330 Shares of Zimmer Biomet (ZBH) Stock
www.americanbankingnews.com - May 1 at 7:34 PM
Stephanie Link adds to Zimmer Biomet after earnings & bets on one gambling giantStephanie Link adds to Zimmer Biomet after earnings & bets on one gambling giant
finance.yahoo.com - May 1 at 4:59 PM
Zimmer Biomet Partners with Faith In Practice to Improve Access to Musculoskeletal Care in GuatemalaZimmer Biomet Partners with Faith In Practice to Improve Access to Musculoskeletal Care in Guatemala
finance.yahoo.com - May 1 at 8:48 AM
Zimmer Biomet (ZBH) Forecasted to Earn FY2019 Earnings of $8.05 Per ShareZimmer Biomet (ZBH) Forecasted to Earn FY2019 Earnings of $8.05 Per Share
www.americanbankingnews.com - May 1 at 7:26 AM
Zimmer Biomet (ZBH) Expected to Post Q2 2018 Earnings of $1.90 Per ShareZimmer Biomet (ZBH) Expected to Post Q2 2018 Earnings of $1.90 Per Share
www.americanbankingnews.com - May 1 at 7:26 AM
Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Smith & Nephew, Stryker, ViewRay, and Zimmer BiometQuotidian Technical Highlights on Selected Medical Equipment Stocks -- Smith & Nephew, Stryker, ViewRay, and Zimmer Biomet
www.prnewswire.com - April 30 at 6:31 AM
William Blair Analysts Reduce Earnings Estimates for Zimmer Biomet (ZBH)William Blair Analysts Reduce Earnings Estimates for Zimmer Biomet (ZBH)
www.americanbankingnews.com - April 30 at 2:32 AM
Piper Jaffray Equities Analysts Reduce Earnings Estimates for Zimmer Biomet (ZBH)Piper Jaffray Equities Analysts Reduce Earnings Estimates for Zimmer Biomet (ZBH)
www.americanbankingnews.com - April 30 at 1:06 AM
Q2 2018 EPS Estimates for Zimmer Biomet (ZBH) Lifted by Leerink SwannQ2 2018 EPS Estimates for Zimmer Biomet (ZBH) Lifted by Leerink Swann
www.americanbankingnews.com - April 30 at 1:06 AM
$1.99 Billion in Sales Expected for Zimmer Biomet (ZBH) This Quarter$1.99 Billion in Sales Expected for Zimmer Biomet (ZBH) This Quarter
www.americanbankingnews.com - April 28 at 2:30 AM
Zimmer Biomet (ZBH) Upgraded at Zacks Investment ResearchZimmer Biomet (ZBH) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 27 at 4:19 PM
Needham & Company LLC Cuts Zimmer Biomet (ZBH) Price Target to $146.00Needham & Company LLC Cuts Zimmer Biomet (ZBH) Price Target to $146.00
www.americanbankingnews.com - April 27 at 11:27 AM
Morgan Stanley Trims Zimmer Biomet (ZBH) Target Price to $140.00Morgan Stanley Trims Zimmer Biomet (ZBH) Target Price to $140.00
www.americanbankingnews.com - April 27 at 11:09 AM
Zimmer Biomet (ZBH) Price Target Cut to $133.00 by Analysts at JMP SecuritiesZimmer Biomet (ZBH) Price Target Cut to $133.00 by Analysts at JMP Securities
www.americanbankingnews.com - April 27 at 11:09 AM
Edited Transcript of ZBH earnings conference call or presentation 26-Apr-18 12:30pm GMTEdited Transcript of ZBH earnings conference call or presentation 26-Apr-18 12:30pm GMT
finance.yahoo.com - April 27 at 8:59 AM
Zimmer Biomet (ZBH) Expected to Post Earnings of $1.87 Per ShareZimmer Biomet (ZBH) Expected to Post Earnings of $1.87 Per Share
www.americanbankingnews.com - April 26 at 7:18 PM
Zimmer Biomet Q1 revenues up 2%; updates guidanceZimmer Biomet Q1 revenues up 2%; updates guidance
seekingalpha.com - April 26 at 5:01 PM
Zimmer Biomets (ZBH) CEO Bryan Hanson on Q1 2018 Results - Earnings Call TranscriptZimmer Biomet's (ZBH) CEO Bryan Hanson on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 5:01 PM
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, Margins DropZimmer Biomet (ZBH) Q1 Earnings Top Estimates, Margins Drop
finance.yahoo.com - April 26 at 5:01 PM
Zimmer Biomet (ZBH) Announces Quarterly  Earnings ResultsZimmer Biomet (ZBH) Announces Quarterly Earnings Results
www.americanbankingnews.com - April 26 at 4:36 PM
Zimmer Biomet (ZBH) Issues FY18 Earnings GuidanceZimmer Biomet (ZBH) Issues FY18 Earnings Guidance
www.americanbankingnews.com - April 26 at 11:19 AM
Zimmer Biomet beats by $0.02, beats on revenueZimmer Biomet beats by $0.02, beats on revenue
seekingalpha.com - April 26 at 8:36 AM
Zimmer Biomet profit slides 42%Zimmer Biomet profit slides 42%
www.marketwatch.com - April 26 at 8:36 AM
Zimmer Biomet (ZBH) Beats on Q1 Earnings & Revenue EstimatesZimmer Biomet (ZBH) Beats on Q1 Earnings & Revenue Estimates
finance.yahoo.com - April 26 at 8:36 AM
Interesting ZBH Put And Call Options For December 21stInteresting ZBH Put And Call Options For December 21st
www.nasdaq.com - April 25 at 5:12 PM
Royal Bank of Canada Increases Zimmer Biomet (ZBH) Price Target to $140.00Royal Bank of Canada Increases Zimmer Biomet (ZBH) Price Target to $140.00
www.americanbankingnews.com - April 20 at 6:24 PM
Zimmer Biomet (ZBH) Earns Buy Rating from BMO Capital MarketsZimmer Biomet (ZBH) Earns Buy Rating from BMO Capital Markets
www.americanbankingnews.com - April 19 at 5:50 PM
Zimmer Biomet (ZBH) Upgraded to "Buy" by GuggenheimZimmer Biomet (ZBH) Upgraded to "Buy" by Guggenheim
www.americanbankingnews.com - April 18 at 9:10 PM

SEC Filings

Zimmer Biomet (NYSE:ZBH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Zimmer Biomet (NYSE:ZBH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Zimmer Biomet (NYSE ZBH) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.